Home › Companies › HALOZYME THERAPEUTICS INC. › 2023-2024

HALOZYME THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and HALOZYME THERAPEUTICS INC.’s Form 8-K, filed April 26, 2024 (Item 5.07 on EDGAR). Page generated October 14, 2026.

5Ballot items
431Asset managers
3,006Fund votes
April 25, 2024Meeting date

Results at a glance

Meeting of April 25, 2024: 5 items on HALOZYME THERAPEUTICS INC.’s Form 8-K, filed April 26, 2024: 3 approved · 2 without a stated outcome.

Material dissent

None.

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore HALOZYME THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by HALOZYME THERAPEUTICS INC.

These tallies are HALOZYME THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed April 26, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

HALOZYME THERAPEUTICS INC. — official shareholder meeting results, meeting held April 25, 2024
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Barbara Duncan	90,120,424	15,016,536	161,704	--	10,383,116	86%	Not verified	—
Elect Director: Mahesh Krishnan, M.D.	103,968,663	1,164,017	165,984	--	10,383,116	99%	Not verified	—
2. The advisory vote on the compensation of the Company's named executive officers	102,860,435	2,190,603	247,626	--	10,383,116	98%	Approved	—
3. A proposal to approve an amendment to the Company's Amended and Restated Certificate of Incorporation to reflect Delaware law provisions regarding exculpation of officers	91,512,252	13,612,616	173,796	--	10,383,116	87%	Approved	—
4. A proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024	114,912,469	647,868	121,443	--	--	99.4%	Approved	—

This meeting is also recorded here as April 26, 2024; both records come from the same filing, so the date should be checked against it.

Source: HALOZYME THERAPEUTICS INC., Form 8-K, filed with the SEC on April 26, 2024 — read the filing on EDGAR.

How asset managers voted at the HALOZYME THERAPEUTICS INC. 2023-2024 meeting

Each item below shows how the 431 asset managers that disclosed a HALOZYME THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Barbara Duncan

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 5 wordings of this item as funds reported it.

86% Majority: yes · of votes cast

FOR 86%AGAINST

FOR: 90,120,424AGAINST: 15,016,536

Details: description as filed, official tally, votes by 122 asset managers

Description as filed by funds: Election of Class II Directors: Barbara Duncan

HALOZYME THERAPEUTICS INC.’s own tally for this item (“Elect Director: Barbara Duncan”): 90,120,424 for, 15,016,536 against, per its Form 8-K filed April 26, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 86% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 122 asset managers below reported 52,576,135 for, 7,776,543 against, 62,687 abstained.

FOR

FOR: 52,576,135AGAINST: 7,776,543ABSTAIN: 62,687

Largest asset managers voting on “Election of Class II Directors: Barbara Duncan” at HALOZYME THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	14,892,835	0	0	For
BlackRock	10,711,138	0	0	For
Fidelity	3,209,068	44,852	0	For
State Street	58,372	2,768,522	0	Against
Delaware/Macquarie	0	2,076,163	0	Against
Artisan	2,028,425	0	0	For
Charles Schwab	1,720,061	0	0	For
Thrivent	1,695,443	0	0	For
JPMorgan	1,623,745	0	0	For
TIAA	1,460,481	0	0	For
First Trust	1,201,533	0	0	For
AllianceBernstein	1,059,054	0	0	For
Invesco	0	1,004,224	0	Against
T. Rowe Price	970,596	0	0	For
Dimensional	815,846	0	0	For
Jackson National	455,295	340,856	0	Mixed
Equitable	720,924	0	0	For
American Century	682,192	0	0	For
Brighthouse	144,234	413,107	61,921	Mixed
AB DISCOVERY GROWTH FUND, INC.	500,392	0	0	For
BUFFALO FUNDS	482,634	0	0	For
Federated Hermes	468,804	0	0	For
AIG/SunAmerica	461,935	0	0	For
Columbia Threadneedle	380,360	0	0	For
MERIDIAN FUND INC	372,820	0	0	For

Showing the 25 largest of 122 asset managers. See all 122 in the interactive database.

2. Elect Director: Mahesh Krishnan, M.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 5 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 103,968,663AGAINST: 1,164,017

Details: description as filed, official tally, votes by 122 asset managers

Description as filed by funds: Election of Class II Directors: Mahesh Krishnan

HALOZYME THERAPEUTICS INC.’s own tally for this item (“Elect Director: Mahesh Krishnan, M.D.”): 103,968,663 for, 1,164,017 against, per its Form 8-K filed April 26, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 122 asset managers below reported 60,091,787 for, 260,891 against, 62,687 abstained.

FOR

FOR: 60,091,787AGAINST: 260,891ABSTAIN: 62,687

Largest asset managers voting on “Election of Class II Directors: Mahesh Krishnan” at HALOZYME THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	14,892,835	0	0	For
BlackRock	10,711,138	0	0	For
Fidelity	3,209,068	44,852	0	For
State Street	2,826,894	0	0	For
Delaware/Macquarie	2,076,163	0	0	For
Artisan	2,028,425	0	0	For
Charles Schwab	1,720,061	0	0	For
Thrivent	1,695,443	0	0	For
JPMorgan	1,623,745	0	0	For
TIAA	1,460,481	0	0	For
First Trust	1,201,533	0	0	For
AllianceBernstein	1,059,054	0	0	For
Invesco	1,004,224	0	0	For
T. Rowe Price	970,596	0	0	For
Dimensional	815,846	0	0	For
Jackson National	796,151	0	0	For
Equitable	720,924	0	0	For
American Century	682,192	0	0	For
Brighthouse	557,341	0	61,921	Mixed
AB DISCOVERY GROWTH FUND, INC.	500,392	0	0	For
BUFFALO FUNDS	482,634	0	0	For
Federated Hermes	468,804	0	0	For
AIG/SunAmerica	461,935	0	0	For
Columbia Threadneedle	380,360	0	0	For
MERIDIAN FUND INC	372,820	0	0	For

Showing the 25 largest of 122 asset managers. See all 122 in the interactive database.

3. 3. A proposal to approve an amendment to the Company's Amended and Restated Certificate of Incorporation to reflect…

Official resultCORPORATE GOVERNANCEReported outcome: Approved

Combines 6 wordings of this item as funds reported it.

87% Approved · of votes cast

FOR 87%

FOR: 91,512,252AGAINST: 13,612,616

Details: description as filed, official tally, votes by 122 asset managers

Description as filed by funds: To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to reflect Delaware law provisions regarding exculpation of officers.

HALOZYME THERAPEUTICS INC.’s own tally for this item (“3. A proposal to approve an amendment to the Company's Amended and Restated Certificate of Incorporation to reflect Delaware law provisions regarding exculpation of officers”): 91,512,252 for, 13,612,616 against — passed, per its Form 8-K filed April 26, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The foregoing proposal was approved.”
Support: 87% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 122 asset managers below reported 55,677,455 for, 4,675,989 against, 61,921 abstained.

FOR

FOR: 55,677,455AGAINST: 4,675,989ABSTAIN: 61,921

Largest asset managers voting on “To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to reflect Delaware” at HALOZYME THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	13,782,699	1,110,136	0	Mixed
BlackRock	10,711,138	0	0	For
Fidelity	2,961,922	291,998	0	Mixed
State Street	2,826,749	145	0	For
Delaware/Macquarie	2,076,163	0	0	For
Artisan	2,028,425	0	0	For
Charles Schwab	1,720,061	0	0	For
Thrivent	1,695,443	0	0	For
JPMorgan	0	1,623,745	0	Against
TIAA	1,460,481	0	0	For
First Trust	1,201,533	0	0	For
AllianceBernstein	1,059,054	0	0	For
Invesco	1,004,224	0	0	For
T. Rowe Price	970,596	0	0	For
Dimensional	815,846	0	0	For
Jackson National	628,733	167,418	0	Mixed
Equitable	720,924	0	0	For
American Century	682,192	0	0	For
Brighthouse	557,341	0	61,921	Mixed
AB DISCOVERY GROWTH FUND, INC.	500,392	0	0	For
BUFFALO FUNDS	482,634	0	0	For
Federated Hermes	468,804	0	0	For
AIG/SunAmerica	461,935	0	0	For
Columbia Threadneedle	380,360	0	0	For
MERIDIAN FUND INC	0	372,820	0	Against

Showing the 25 largest of 122 asset managers. See all 122 in the interactive database.

4. 2. The advisory vote on the compensation of the Company's named executive officers

Official result Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 18 wordings of this item as funds reported it.

98% Approved · of votes cast

FOR 98%

FOR: 102,860,435AGAINST: 2,190,603

Details: description as filed, official tally, votes by 426 asset managers

Description as filed by funds: To approve, by a non-binding advisory vote, the compensation of the Company's named executive officers.

HALOZYME THERAPEUTICS INC.’s own tally for this item (“2. The advisory vote on the compensation of the Company's named executive officers”): 102,860,435 for, 2,190,603 against — passed, per its Form 8-K filed April 26, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The foregoing proposal was approved.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 122 asset managers voting on “To approve, by a non-binding advisory vote, the compensation of the Company's named executive officers.” at HALOZYME THERAPEUTICS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	14,892,835	0	For
BlackRock	10,711,138	0	For
Artisan	5,263,684	0	For
Fidelity	3,253,920	0	For
State Street	2,826,894	0	For
Delaware/Macquarie	2,076,163	0	For
Charles Schwab	1,720,061	0	For
Thrivent	1,695,443	0	For
JPMorgan	1,623,745	0	For
TIAA	1,460,481	0	For
First Trust	1,201,533	0	For
AllianceBernstein	1,059,054	0	For
Invesco	1,004,224	0	For
T. Rowe Price	970,596	0	For
Dimensional	815,846	0	For
Jackson National	796,151	0	For
Equitable	720,924	0	For
American Century	682,192	0	For
Brighthouse	557,341	61,921	Mixed
AB DISCOVERY GROWTH FUND, INC.	500,392	0	For
BUFFALO FUNDS	482,634	0	For
Federated Hermes	468,804	0	For
AIG/SunAmerica	461,935	0	For
Columbia Threadneedle	380,360	0	For
MERIDIAN FUND INC	372,820	0	For

Fund voting reports, all 122 managers: 63,368,956 for, 191,746 against, 61,921 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 341 asset managers voting on “To approve, by a non-binding advisory vote, the compensation of the Company's named executive officers.” at HALOZYME THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Vote
State Street	6,135,781	0	For
New York Life	5,000,000	0	For
BlackRock	4,679,194	997	For
SNYDER CAPITAL MANAGEMENT L P	3,592,472	0	For
AllianceBernstein	3,399,831	0	For
GEODE CAPITAL MANAGEMENT, LLC	2,941,522	0	For
JPMorgan	2,528,690	0	For
GW&K Investment Management, LLC	1,890,859	0	For
ArrowMark Colorado Holdings LLC	1,849,642	0	For
Charles Schwab	1,759,686	0	For
Thrivent	1,725,191	0	For
Nuveen	1,611,309	0	For
MELLON INVESTMENTS Corp	1,378,187	0	For
T. Rowe Price	1,226,978	0	For
Invesco	1,184,319	0	For
Stephens Investment Management Group LLC	1,166,281	0	For
Epoch Investment Partners, Inc.	1,146,048	0	For
Man Group plc	1,087,890	0	For
NEW YORK STATE COMMON RETIREMENT FUND	917,782	0	For
Granite Investment Partners, LLC	734,205	0	For
American Century	703,278	0	For
Lazard	691,143	0	For
Allspring	638,223	0	For
PRINCIPAL GLOBAL INVESTORS	557,295	0	For
Northern Trust	527,600	90	For

Institutional-manager reports, all 341 managers: 62,974,816 for, 1,426,977 against, 32,850 abstained, 908 not voted, 979 unknown. Showing the 25 largest; see all in the interactive database.

5. 4. A proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 6 wordings of this item as funds reported it.

99.4% Approved · of votes cast

FOR 99.4%

FOR: 114,912,469AGAINST: 647,868

Details: description as filed, official tally, votes by 122 asset managers

Description as filed by funds: To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.

HALOZYME THERAPEUTICS INC.’s own tally for this item (“4. A proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024”): 114,912,469 for, 647,868 against — passed, per its Form 8-K filed April 26, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The foregoing proposal was approved.”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of HALOZYME THERAPEUTICS INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Ratify Appointment of Independent Auditors” (2 managers, 46,783 for).

The 122 asset managers below reported 60,309,472 for, 43,972 against, 61,921 abstained.

FOR

FOR: 60,309,472AGAINST: 43,972ABSTAIN: 61,921

Largest asset managers voting on “To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm fo” at HALOZYME THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	14,892,835	0	0	For
BlackRock	10,711,138	0	0	For
Fidelity	3,253,920	0	0	For
State Street	2,826,749	145	0	For
Delaware/Macquarie	2,076,163	0	0	For
Artisan	2,028,425	0	0	For
Charles Schwab	1,720,061	0	0	For
Thrivent	1,695,443	0	0	For
JPMorgan	1,623,745	0	0	For
TIAA	1,460,481	0	0	For
First Trust	1,201,533	0	0	For
AllianceBernstein	1,059,054	0	0	For
Invesco	1,004,224	0	0	For
T. Rowe Price	970,596	0	0	For
Dimensional	815,846	0	0	For
Jackson National	796,151	0	0	For
Equitable	720,924	0	0	For
American Century	682,192	0	0	For
Brighthouse	557,341	0	61,921	Mixed
AB DISCOVERY GROWTH FUND, INC.	500,392	0	0	For
BUFFALO FUNDS	482,634	0	0	For
Federated Hermes	468,804	0	0	For
AIG/SunAmerica	461,935	0	0	For
Columbia Threadneedle	380,360	0	0	For
MERIDIAN FUND INC	372,820	0	0	For

Showing the 25 largest of 122 asset managers. See all 122 in the interactive database.

Not shown here: this season’s fund filings also report 1 item from the meeting of May 1, 2025, which belongs to the 2024-2025 season. A meeting outside this season’s July 1 to June 30 window is not counted in this page’s items or in its totals of asset managers and fund votes.

Largest HALOZYME THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 127,186,000 shares outstanding at the time of that meeting.

Fund voting reports: top HALOZYME THERAPEUTICS INC. shareholders by shares voted on “To approve, by a non-binding advisory vote, the compensation of the Company's named executive…”, 2023-2024
#	Asset manager	% of shares outstanding
1	Vanguard	11.71%
2	BlackRock	8.42%
3	Artisan	4.14%
4	Fidelity	2.56%
5	State Street	2.22%
6	Delaware/Macquarie	1.63%
7	Charles Schwab	1.35%
8	Thrivent	1.33%
9	JPMorgan	1.28%
10	TIAA	1.15%

Institutional-manager reports: top HALOZYME THERAPEUTICS INC. shareholders by shares voted on “To approve, by a non-binding advisory vote, the compensation of the Company's named executive…”, 2023-2024
#	Asset manager	% of shares outstanding
1	State Street	4.82%
2	New York Life	3.93%
3	BlackRock	3.68%
4	SNYDER CAPITAL MANAGEMENT L P	2.82%
5	AllianceBernstein	2.67%
6	GEODE CAPITAL MANAGEMENT, LLC	2.31%
7	JPMorgan	1.99%
8	GW&K Investment Management, LLC	1.49%
9	ArrowMark Colorado Holdings LLC	1.45%
10	Charles Schwab	1.38%

Reported HALOZYME THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

HALOZYME THERAPEUTICS INC. holdings and ownership disclosed for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
BlackRock	10.11%	13F
Vanguard Group	9.14%	13F
Artisan Partners Limited Partnership	5.26%	DEF14A
State Street	5.10%	13F
Geode Capital	2.38%	13F
Helen I. Torley	1.89%	DEF14A
Invesco	1.64%	13F
Northern Trust	1.41%	13F
Morgan Stanley	1.37%	13F
Dimensional Fund Advisors	1.33%	13F

Percentages above are of 127,186,000 shares outstanding, as reported by HALOZYME THERAPEUTICS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from HALOZYME THERAPEUTICS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.

At HALOZYME THERAPEUTICS INC.'s shareholder meeting held April 25, 2024, in the 2023-2024 proxy season, 431 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 3,006 separate fund positions. On the most widely held item on that ballot — To approve, by a non-binding advisory vote, the compensation of the Company's named executive… — HALOZYME THERAPEUTICS INC.'s filing reports the proposal as approved, with 98% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: HALOZYME THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on April 26, 2024.

HALOZYME THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.